HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs